z-logo
open-access-imgOpen Access
A2B Adenosine Receptors Protect against Sepsis-Induced Mortality by Dampening Excessive Inflammation
Author(s) -
Balázs Csóka,
Zoltán H. Németh,
Peter Rosenberger,
Holger K. Eltzschig,
Z. Spolarics,
Pál Pacher,
Zsolt Selmeczy,
Balázs Koscsó,
Leonóra Himer,
E. Sylvester Vizi,
Michael R. Blackburn,
Edwin A. Deitch,
György Haskó
Publication year - 2010
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.0901295
Subject(s) - sepsis , receptor , inflammation , adenosine a3 receptor , chemokine , immunology , knockout mouse , adenosine receptor , purinergic signalling , adenosine , biology , agonist , medicine , endocrinology
Despite intensive research, efforts to reduce the mortality of septic patients have failed. Adenosine is a potent extracellular signaling molecule, and its levels are elevated in sepsis. Adenosine signals through G-protein-coupled receptors and can regulate the host's response to sepsis. In this study, we studied the role of A(2B) adenosine receptors in regulating the mortality and inflammatory response of mice following polymicrobial sepsis. Genetic deficiency of A(2B) receptors increased the mortality of mice suffering from cecal ligation and puncture-induced sepsis. The increased mortality of A(2B) knockout mice was associated with increased levels of inflammatory cytokines and chemokines and augmented NF-kappaB and p38 activation in the spleen, heart, and plasma in comparison with wild-type animals. In addition, A(2B) receptor knockout mice showed increased splenic apoptosis and phosphatase and tensin homolog activation and decreased Akt activation. Experiments using bone-marrow chimeras revealed that it is the lack of A(2B) receptors on nonhematopoietic cells that is primarily responsible for the increased inflammation of septic A(2B) receptor-deficient mice. These results indicate that A(2B) receptor activation may offer a new therapeutic approach for the management of sepsis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom